Source comparison
Tesamorelin + Ipamorelin Blend Clinical Trials 2026: Study Design Comparison
Understanding the trial architecture is essential for interpreting results and assessing external validity. The table below maps the three active trials in the 2026 program across key design parameters. SYNERGY-1 Adults 40–65 with abdominal obesity + metabolic
This comparison does not assign a generated winner or score.
- Understanding the trial architecture is essential for interpreting results and assessing external validity. The table below maps the three active trials in the 2026 program across key design parameters.
- SYNERGY-1
- Adults 40–65 with abdominal obesity + metabolic syndrome criteria
- Absolute VAT volume change (L4–L5 MRI) at 26 weeks
- 26 weeks active + 12 weeks washout
- 420 participants
- Interim results released March 2026; final readout Q3 2026
- Gold-standard visceral fat quantification with MRI provides objective, reproducible endpoint. Strongest evidence base for regulatory consideration
- SYNERGY-2
- Adults 35–70 with MASLD (liver fat >5% by MRI-PDFF)
- Relative liver fat content change at 24 weeks
- 24 weeks active
- 180 participants
- Enrollment complete; readout Q4 2026
- Liver-specific endpoint addresses unmet need in MASLD where no pharmacologic treatments are FDA-approved. High clinical relevance if positive
- SYNERGY-3
- SYNERGY-1 completers willing to continue
- Maintenance of VAT reduction at 52 weeks post-treatment
- 52 weeks observational follow-up
- 150 participants (subset of SYNERGY-1)
- Ongoing; completion Q1 2027
- Durability data critical for understanding whether metabolic benefits persist or reverse after GH normalization. Addresses real-world sustainability question
- SYNERGY-1 represents the regulatory path forward if outcomes remain consistent through final analysis. The 18.4% VAT reduction in interim data exceeds the 10–12% threshold typically considered clinically meaningful for metabolic risk reduction, and the concurrent lean mass gain differentiates the combination from GLP-1 receptor agonists, which produce similar fat loss but often with 20–40% of weight loss coming from lean tissue. SYNERGY-2's liver-focused design positions the combination as a potential disease-modifying therapy for MASLD, a condition affecting an estimated 30% of adults globally with no approved pharmacologic options beyond lifestyle modification. SYNERGY-3's durability assessment will determine whether the combination requires continuous dosing or if metabolic benefits persist long enough post-treatment to justify intermittent cycles. A dosing model that would substantially improve cost-effectiveness and patient acceptance.